On Oct. 13, 2020, Cue Health announced a $481 Million award from the Department of Defense (DOD), on behalf of the U.S. Department of Health and Human Services (HHS), to expand Cueﾒs U.S.-based production capacity and deploy six million molecular, point-of-care Cue COVID-19 Tests by March 2021.

This effort, intended to help Cue onshore its supply chain and rapidly increase its production capacity, was being led by the DOD, and was funded through the HHS to enable and support domestic production of critical medical resources. Manufacturing of the Cue COVID-19 Test Cartridges will be performed exclusively at Cueﾒs facilities in San Diego, California.